BL-1020 Mesylate
| Code | Size | Price |
|---|
| TAR-T26834-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T26834-50mg | 50mg | £1,661.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T26834-100mg | 100mg | £2,079.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
BL-1020 is a GABA A receptor agonist and dopamine receptor antagonist. BL-1020 is an ester of GABA and perphenazine, and pharmacologically it acts as a GABA agonist and D2 antagonist. BL-1020 has shown pro-cognitive effects in the trials.
CAS:
916898-61-8
Formula:
C26H37ClN4O5S2
Molecular Weight:
585.18
Purity:
0.98
SMILES:
CS(O)(=O)=O.NCCCC(=O)OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1
References
1. Thyme S, Song Y. Computational Design of DNA-Binding Proteins. Methods Mol Biol. 2016;1414:265-83. doi: 10.1007/978-1-4939-3569-7_16. PubMed PMID: 27094297.
2. Geffen Y, Keefe R, Rabinowitz J, Anand R, Davidson M. Bl-1020, a new ?-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study. J Clin Psychiatry. 2012 Sep;73(9):e1168-74. doi: 10.4088/JCP.12m07642. PubMed PMID: 23059159.
3. Anand R, Geffen Y, Vasile D, Dan I. An open-label tolerability study of BL-1020 antipsychotic: a novel gamma aminobutyric acid ester of perphenazine. Clin Neuropharmacol. 2010 Nov-Dec;33(6):297-302. doi: 10.1097/WNF.0b013e3181f8d501. PubMed PMID: 20921890.
4. Fitzgerald PB. BL-1020, an oral antipsychotic agent that reduces dopamine activity and enhances GABAA activity, for the treatment of schizophrenia. Curr Opin Investig Drugs. 2010 Jan;11(1):92-100. Review. PubMed PMID: 20047163.